Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjuvant hormonal therapy.

Yasuhiro Tamaki1, Yasuo Miyoshi, Shinzaburo Noguchi

  • 1Department of Surgical Oncology, Osaka University Graduate School of Medicine, 2-2-E10 Yamadaoka, Suita, Osaka 565-0871, Japan. tamaki@onsurg.med.osaka-u.ac.jp

Breast Cancer (Tokyo, Japan)
|August 20, 2002
PubMed
Summary

New guidelines recommend 5 years of tamoxifen for estrogen receptor-positive breast cancer. Premenopausal women with high-risk tumors may benefit from ovarian suppression alongside tamoxifen.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Apocrine carcinoma of the breast: distinctive metabolic reprogramming and high-frequency PIK3CA mutations revealed by molecular and immunohistochemical analysis.

Histopathology·2025
Same author

Erratum: Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Practice guidelines on endoscopic surgery for qualified surgeons by the endoscopic surgical skill qualification system: Breast.

Asian journal of endoscopic surgery·2024
Same author

Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancer.

Breast cancer (Tokyo, Japan)·2023
Same author

Validation of the prognosis of patients with ER‑positive, HER2‑negative and node‑negative invasive breast cancer classified as low risk by Curebest<sup>™</sup> 95GC Breast in a multi‑institutional registry study.

Oncology letters·2023

Area of Science:

  • Oncology
  • Endocrinology
  • Clinical Guidelines

Background:

  • Recent consensus conferences (NIH, 2000; 7th International Conference, 2001) updated adjuvant hormonal therapy guidelines for primary breast cancer.
  • Estrogen receptor (ER) and/or progesterone receptor (PR) status is crucial for treatment decisions.

Purpose of the Study:

  • To summarize the consensus recommendations for adjuvant hormonal therapy in primary breast cancer.
  • To outline treatment strategies based on menopausal status, tumor receptor status, and risk assessment.

Main Methods:

  • Guidelines based on consensus statements from major national and international conferences.
  • Recommendations derived from expert consensus on adjuvant therapy for ER/PR-positive breast cancer.

Related Experiment Videos

Main Results:

  • Adjuvant hormonal therapy is recommended for all patients with ER and/or PR-positive tumors.
  • Five years of tamoxifen is the standard therapy for both premenopausal and postmenopausal patients.
  • Ovarian ablation or suppression with tamoxifen is recommended for premenopausal women with high-risk tumors.

Conclusions:

  • Hormonal therapy selection should consider relapse risk, side effects, and patient preferences.
  • Chemotherapy combinations should be individualized based on comprehensive patient assessment.